Completed PHASE3 INTERVENTIONAL NCT00209456

Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia

GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title

Sponsor: GE Healthcare

Conditions Alzheimer's Lewy Body Dementia Non-DLB Dementia Vascular Dementia

Interventions DatSCAN

Updated 7 times since 2017 Last updated: May 15, 2007 Started: Nov 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00209456, this PHASE3 trial focuses on Alzheimer's and Lewy Body Dementia and remains completed. Sponsored by GE Healthcare, it has been updated 7 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Study Description(click to expand)

GEHC had decided notto provide this detail

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Sep 2020 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GE Healthcare

Data source: GE Healthcare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ismaning, Germany